• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重性抑郁障碍的躯体性疼痛症状及其治疗转归:一项 STAR*D(缓解抑郁的序贯治疗选择)研究报告。

Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.

机构信息

Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024-1759, USA.

出版信息

Psychol Med. 2010 Feb;40(2):239-51. doi: 10.1017/S0033291709006035. Epub 2009 Jun 3.

DOI:10.1017/S0033291709006035
PMID:19493369
Abstract

BACKGROUND

Painful physical symptoms (PPS) are both common and reduce the likelihood of remission in major depressive disorder (MDD), based upon results of clinical trials in selected populations. Whether PPS significantly contribute to poorer treatment outcome overall in primary or specialty psychiatric care settings remains unclear.

METHOD

Out-patients (n=2876) with MDD were treated in the first step of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial with citalopram up to 60 mg/day for up to 14 weeks. Presence of painful symptoms, as well as severity of depression, physical illness, and demographic and treatment factors were examined. Time to and overall rates of remission were analysed in relation to the presence of PPS.

RESULTS

Of the participants, 80% complained of PPS. These patients, both in primary and specialty psychiatric settings, had significantly lower remission rates and took longer to remit. Increasing severity of PPS was associated with greater physical illness burden, lower socio-economic status, absence of private insurance and being female, African-American or Hispanic. After adjustment for these factors, patients with PPS no longer had significantly poorer treatment outcomes.

CONCLUSIONS

Presence and severity of PPS is an indicator of MDD that may have poorer treatment outcome with an initial selective serotonin reuptake inhibitor. These poorer treatment outcomes are multifactorial, however, and are not explained by the presence and severity of pain per se.

摘要

背景

基于对特定人群临床试验的结果,疼痛的躯体症状(PPS)在重度抑郁症(MDD)中既常见又降低缓解的可能性。在初级或专科精神保健环境中,疼痛躯体症状是否显著导致整体治疗结局更差仍不清楚。

方法

在缓解抑郁症的序贯治疗选择(STAR*D)试验的第一步中,对 MDD 门诊患者(n=2876)用西酞普兰治疗,剂量高达 60 mg/天,最多 14 周。检查疼痛症状的存在情况,以及抑郁、躯体疾病的严重程度、人口统计学和治疗因素。根据 PPS 的存在情况分析缓解的时间和总缓解率。

结果

参与者中有 80%报告有 PPS。这些患者,无论是在初级还是专科精神科环境中,缓解率明显较低,缓解时间更长。PPS 的严重程度增加与躯体疾病负担更大、社会经济地位较低、没有私人保险以及女性、非裔美国人或西班牙裔有关。在调整这些因素后,有 PPS 的患者的治疗结局不再显著更差。

结论

PPS 的存在和严重程度是 MDD 的一个指标,用初始选择性 5-羟色胺再摄取抑制剂治疗可能会有更差的治疗结局。然而,这些更差的治疗结局是多因素的,不能仅用疼痛的存在和严重程度来解释。

相似文献

1
Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.重性抑郁障碍的躯体性疼痛症状及其治疗转归:一项 STAR*D(缓解抑郁的序贯治疗选择)研究报告。
Psychol Med. 2010 Feb;40(2):239-51. doi: 10.1017/S0033291709006035. Epub 2009 Jun 3.
2
Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.重度抑郁症门诊患者中焦虑与物质使用障碍共病:临床特征及对治疗结果的影响
Drug Alcohol Depend. 2009 Jan 1;99(1-3):248-60. doi: 10.1016/j.drugalcdep.2008.08.010. Epub 2008 Nov 5.
3
Ethnicity/race and outcome in the treatment of depression: results from STAR*D.抑郁症治疗中的种族/民族与治疗结果:STAR*D研究结果
Med Care. 2007 Nov;45(11):1043-51. doi: 10.1097/MLR.0b013e3181271462.
4
Relationship between painful physical symptoms and severity of depressive symptomatology and suicidality.疼痛的躯体症状与抑郁症状严重程度和自杀倾向的关系。
Psychiatry Res. 2011 Oct 30;189(3):357-61. doi: 10.1016/j.psychres.2011.01.009. Epub 2011 Feb 16.
5
Insured and non-insured depressed outpatients: how do they compare?参保和未参保的抑郁症门诊患者:他们之间有何差异?
Ann Clin Psychiatry. 2007 Apr-Jun;19(2):73-82. doi: 10.1080/10401230701334671.
6
Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study.重度抑郁症中易激惹的患病率及临床相关因素:缓解抑郁症序列治疗方案研究的初步报告
J Clin Psychiatry. 2005 Feb;66(2):159-66; quiz 147, 273-4.
7
The impact of diabetes on depression treatment outcomes.糖尿病对抑郁症治疗结果的影响。
Gen Hosp Psychiatry. 2010 Jan-Feb;32(1):33-41. doi: 10.1016/j.genhosppsych.2009.07.009. Epub 2009 Aug 27.
8
[Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].[重度抑郁症治疗后的残留症状:在城市进行的门诊观察实践]
Encephale. 2003 Sep-Oct;29(5):438-44.
9
Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report.既往疾病史与抑郁门诊患者的急性或长期结局相关吗?一项 STAR*D 报告。
Psychol Med. 2012 Jun;42(6):1131-49. doi: 10.1017/S0033291711002170. Epub 2011 Oct 19.
10
The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.度洛西汀治疗重度抑郁症试验中疼痛对结果的影响。
Ann Clin Psychiatry. 2008 Oct-Dec;20(4):187-93. doi: 10.1080/10401230802435609.

引用本文的文献

1
Opioids diminish the placebo antidepressant response: Observational post hoc findings from a randomized controlled ketamine trial.阿片类药物会减弱安慰剂的抗抑郁反应:一项随机对照氯胺酮试验的事后观察结果。
J Affect Disord. 2025 Jul 15;381:200-204. doi: 10.1016/j.jad.2025.04.008. Epub 2025 Apr 2.
2
Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression.艾氯胺酮联合选择性5-羟色胺再摄取抑制剂(SSRI)或5-羟色胺及去甲肾上腺素再摄取抑制剂(SNRI)治疗难治性抑郁症
JAMA Psychiatry. 2025 Apr 2. doi: 10.1001/jamapsychiatry.2025.0200.
3
Opioids Diminish the Placebo Antidepressant Response: A Post Hoc Analysis of a Randomized Controlled Ketamine Trial.
阿片类药物会削弱安慰剂的抗抑郁反应:一项关于氯胺酮的随机对照试验的事后分析
medRxiv. 2024 Nov 2:2024.09.24.24314243. doi: 10.1101/2024.09.24.24314243.
4
Painful physical symptoms and antidepressant treatment outcome in depression: a systematic review and meta-analysis.抑郁障碍中躯体性疼痛症状与抗抑郁治疗结局的关系:系统评价和 Meta 分析。
Mol Psychiatry. 2024 Aug;29(8):2560-2567. doi: 10.1038/s41380-024-02496-7. Epub 2024 Mar 13.
5
Roles of microglia in adult hippocampal neurogenesis in depression and their therapeutics.小胶质细胞在抑郁症成年海马神经发生中的作用及其治疗策略。
Front Immunol. 2023 Oct 10;14:1193053. doi: 10.3389/fimmu.2023.1193053. eCollection 2023.
6
Pre-treatment Pain Symptoms Influence Antidepressant Response to Ketamine in Depressive Patients.治疗前疼痛症状影响抑郁症患者对氯胺酮的抗抑郁反应。
Front Psychiatry. 2022 Mar 16;13:793677. doi: 10.3389/fpsyt.2022.793677. eCollection 2022.
7
Changes in Monoaminergic Neurotransmission in an Animal Model of Osteoarthritis: The Role of Endocannabinoid Signaling.骨关节炎动物模型中单胺能神经传递的变化:内源性大麻素信号传导的作用。
Front Mol Neurosci. 2018 Dec 20;11:466. doi: 10.3389/fnmol.2018.00466. eCollection 2018.
8
Major Depression Comorbid with Medical Conditions: Analysis of Quality of Life, Functioning, and Depressive Symptom Severity.重度抑郁症合并躯体疾病:生活质量、功能及抑郁症状严重程度分析
Psychopharmacol Bull. 2018 Jan 15;48(1):8-25.
9
Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine.通过疼痛性躯体症状的早期改善预测重度抑郁症的治疗结果:度洛西汀双盲、安慰剂对照试验的汇总分析
Neuropsychiatr Dis Treat. 2017 Sep 25;13:2457-2467. doi: 10.2147/NDT.S143093. eCollection 2017.
10
Do Somatic Symptoms Predict the Severity of Depression? A Validation Study of the Korean Version of the Depression and Somatic Symptoms Scale.躯体症状能预测抑郁症的严重程度吗?一项关于《抑郁与躯体症状量表》韩语版的验证研究。
J Korean Med Sci. 2016 Dec;31(12):2002-2009. doi: 10.3346/jkms.2016.31.12.2002.